https://www.selleckchem.com/pr....oducts/ionomycin.htm
We used immunohistochemistry to test whether levels of the indicated proteins in respective tumors correlate with RFS and OS. We observed that the presence of high Irf6 levels in the tumors following NATs correlated with reduced RFS and OS. Perhaps not by coincidence, we noticed that trastuzumab-sensitive ErbB2-positive breast cancer cells selected for the ability to overproduce exogenous Irf6 in culture acquired trastuzumab resistance. Finally, EGFR presence in patients' tumors before or after NATs was associated with decreased RFS a
Like
Comment
Share
